Evans, Jeff
The 17-gene Oncotype DX® prostate cancer assay (Genomic Health Inc., Redwood City, California) is a validated, biopsy based gene expression assay that reports the Genomic Prostate Score. Combined with clinical risk features, GPS provides an individualized estimation of disease aggressiveness at dia...
prostate cancer; prolonged nighttime fasting; early time-restricted feeding; circadian rhythms; breakfast; chrononutrition1. Introduction Prostate cancer is the most frequently diagnosed cancer in men and ranks as the third cause of cancer mortality in Spain [1]. Several non-modifiable risk factors ...
1. Introduction Skeletal metastases are a frequent complication of prostate cancer (PCa) and a major cause of morbidity and mortality in patients with advanced disease [1,2]. Proliferation of PCa cells within the bone promotes localized bone turnover, resulting in primarily osteosclerotic lesions ...
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression-free and overall survival than bicalutamide (BIC)-ADT. Accordin...
Understanding Prostate Cancer 2e PaperAnatomical Chart Company
Understanding Prostate Cancer 2e LaminatedAnatomical Chart Company
These findings suggest that there is no active recruitment of DC into prostate cancer and those DC present are only minimally activated.Troy ADavidson PAtkinson CHart DThe Journal of UrologyTroy A,Davidson P,Atkinson C,et al.Phenotypic characterisation of the dendritic cell infiltrate in prostate ...
Identification of the Treatment Pathway of Metastatic Castrate-Resistant Prostate Cancer in Scotland: A Chart Review* A representative panel of urologists and oncologists was contacted to identify patients diagnosed with mCRPC who met the inclusion criteria described in Table 1.* Patient data reflect ...
Latent class analysis of triazole-naive patients identified a nondiseased group and 3 disease classes: class 1 (n = 49, 37.7%) represented patients with or without positive RT-PCR but no immunologic response to A fumigatus and negative GM (nondiseased); class 2 (n = 23, 17.7%) ...